- Home
- IMNN
IMNN
Imunon Inc.
as 11-03-2025 4:00pm EST
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Upcoming Earnings Alert:
Get ready for potential market movements as Imunon Inc. IMNN prepares to release earnings report on 05 Nov 2025.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAWRENCEVILLE |
| Market Cap: | 12.9M | IPO Year: | 1985 |
| Target Price: | $182.61 | AVG Volume (30 days): | 79.1K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.33 - $41.22 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Imunon Inc. News
IMNN Breaking Stock News: Dive into IMNN Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
GlobeNewswire
11 days ago
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
GlobeNewswire
14 days ago
DNA Cancer Vaccine Clinical Trials & Market Opportunity Outlook 2026 | First Commercial Approval of DNA Cancer Vaccine Anticipated by 2030
GlobeNewswire
18 days ago
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
GlobeNewswire
21 days ago
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
GlobeNewswire
2 months ago
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
Zacks Small Cap Research
4 months ago
OTC Markets Hosts Virtual Investor Presentation with Stacy Lindborg, President, CEO, and Board Director of Imunon, and David Bautz, PhD, Senior Analyst at Zacks SCR
Zacks Small Cap Research
4 months ago
IMNN: Translational Data from OVATION 2 Presented…
Compare IMNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNN Imunon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.